ATE395905T1 - Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs - Google Patents
Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebsInfo
- Publication number
- ATE395905T1 ATE395905T1 AT05791660T AT05791660T ATE395905T1 AT E395905 T1 ATE395905 T1 AT E395905T1 AT 05791660 T AT05791660 T AT 05791660T AT 05791660 T AT05791660 T AT 05791660T AT E395905 T1 ATE395905 T1 AT E395905T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical compositions
- cancer
- treatment
- solid dispersions
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60475304P | 2004-08-27 | 2004-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE395905T1 true ATE395905T1 (de) | 2008-06-15 |
Family
ID=35539162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05791660T ATE395905T1 (de) | 2004-08-27 | 2005-08-29 | Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs |
Country Status (10)
Country | Link |
---|---|
US (2) | US20060078617A1 (de) |
EP (1) | EP1796642B1 (de) |
JP (1) | JP5128948B2 (de) |
CN (1) | CN101048140B (de) |
AT (1) | ATE395905T1 (de) |
CA (1) | CA2578442A1 (de) |
DE (1) | DE602005007048D1 (de) |
ES (1) | ES2306216T3 (de) |
MX (1) | MX2007002398A (de) |
WO (1) | WO2006026501A1 (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000041698A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1478358B1 (de) | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib Tosylate zur Behandlung von durch unnormale Angiogenese gekennzeichneten Krankheiten |
NZ562413A (en) * | 2003-02-21 | 2009-02-28 | Resmed Ltd | Headgear assembly for nasal pillows mask |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
EP1626714B1 (de) | 2003-05-20 | 2007-07-04 | Bayer Pharmaceuticals Corporation | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
SI1663978T1 (sl) * | 2003-07-23 | 2008-02-29 | Bayer Pharmaceuticals Corp | Fluoro substituirana omega-karboksiaril difenil secnina za zdravljenje ali preprecevanje bolezni instanj |
MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
KR20090018224A (ko) * | 2004-09-29 | 2009-02-19 | 바이엘 헬스케어 아게 | 열역학적으로 안정한 형태의 bay 43-9006 토실레이트 |
DE602006017188D1 (de) * | 2005-03-07 | 2010-11-11 | Bayer Schering Pharma Ag | Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs |
JP2009538317A (ja) * | 2006-05-26 | 2009-11-05 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ |
CA2657379A1 (en) * | 2006-07-10 | 2008-01-17 | Elan Pharma International Ltd. | Nanoparticulate sorafenib formulations |
JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
US20100143459A1 (en) * | 2006-11-09 | 2010-06-10 | Abbott Gmbh & Co. Kg | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
EP2305263B1 (de) * | 2007-06-07 | 2012-09-19 | Novartis AG | Stabilisierte amorphe Formen von Imatinib Mesylat |
EP2197426A2 (de) * | 2007-10-19 | 2010-06-23 | Abbott GmbH & Co. KG | Eine verbindung auf n-aryl-harnstoff-basis enthaltendes festes dispersionsprodukt |
CN101220024A (zh) * | 2007-12-11 | 2008-07-16 | 杜晓敏 | 一组抑制激酶的抗癌化合物 |
US20090203709A1 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor |
WO2009106825A1 (en) * | 2008-02-27 | 2009-09-03 | Cipla Limited | Polymorphs of sorafenib and salts thereof |
EP2440531A2 (de) * | 2009-06-12 | 2012-04-18 | Ratiopharm GmbH | 4-[4-[[4-chlor-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridin-2-carboxamid-polymorphe |
WO2011076711A2 (en) | 2009-12-23 | 2011-06-30 | Ratiopharm Gmbh | Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
EP2579855B1 (de) | 2010-06-09 | 2014-09-03 | AbbVie Bahamas Ltd. | Feste dispersionen mit kinaseinhibitoren |
WO2012049253A1 (en) * | 2010-10-14 | 2012-04-19 | Abbott Gmbh & Co. Kg | Curcuminoid solid dispersion formulation |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
RU2598345C2 (ru) | 2010-10-29 | 2016-09-20 | Эббви Инк. | Твердые дисперсии, содержащие средства, вызывающие апоптоз |
WO2012071336A1 (en) | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Salts and crystalline forms of an apoptosis-inducing agent |
CN103402521B (zh) | 2010-11-23 | 2016-01-20 | 艾伯维巴哈马有限公司 | 使用选择性的bcl-2抑制剂的治疗方法 |
EP2559431A1 (de) | 2011-08-17 | 2013-02-20 | Ratiopharm GmbH | Pharmazeutische Zusammensetzung umfassend 4-[4-[[4-Chlor-3-(trifluormethyl)phenyl]carbamoylamin]phenoxy]-N-methyl-pyridin-2-carboxamid |
CN103301066B (zh) * | 2012-03-15 | 2018-12-07 | 苏州泽璟生物制药有限公司 | 一种改善吸收性能的固体分散体及其制备 |
CN103301067B (zh) * | 2012-03-15 | 2018-09-11 | 苏州泽璟生物制药有限公司 | 一种改善吸收性能的固体分散体及其制备 |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
AR096469A1 (es) * | 2013-06-06 | 2015-12-30 | Bayer Pharma AG | Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas |
CN107661296A (zh) * | 2016-07-27 | 2018-02-06 | 江苏先声药业有限公司 | 一种瑞戈非尼固体分散体及其制备方法 |
WO2018035346A1 (en) * | 2016-08-17 | 2018-02-22 | Ichan School Of Medicine At Mount Sinal | Kinase inhibitor compounds, compositions, and methods of treating cancer |
CN111991418A (zh) * | 2020-08-29 | 2020-11-27 | 吴国斌 | 一种壳聚糖载体的载药***及其制备方法 |
JP7428356B2 (ja) * | 2020-12-07 | 2024-02-06 | 天津叡創康泰生物技術有限公司 | 高いバイオアベイラビリティを有するソラフェニブの医薬組成物、ソラフェニブ経口固形製剤、及びその使用 |
WO2023155182A1 (zh) * | 2022-02-21 | 2023-08-24 | 北京睿创康泰医药研究院有限公司 | 一种低服用剂量高药物暴露量的索拉非尼或多纳非尼口服制剂及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2003047523A2 (en) * | 2001-12-04 | 2003-06-12 | Onyx Pharmaceuticals, Inc. | Raf-mek-erk pathway inhibitors to treat cancer |
US20030207872A1 (en) * | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1478358B1 (de) * | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib Tosylate zur Behandlung von durch unnormale Angiogenese gekennzeichneten Krankheiten |
-
2005
- 2005-08-29 AT AT05791660T patent/ATE395905T1/de not_active IP Right Cessation
- 2005-08-29 US US11/212,907 patent/US20060078617A1/en not_active Abandoned
- 2005-08-29 ES ES05791660T patent/ES2306216T3/es active Active
- 2005-08-29 MX MX2007002398A patent/MX2007002398A/es active IP Right Grant
- 2005-08-29 CA CA002578442A patent/CA2578442A1/en not_active Abandoned
- 2005-08-29 EP EP05791660A patent/EP1796642B1/de not_active Not-in-force
- 2005-08-29 JP JP2007533490A patent/JP5128948B2/ja not_active Expired - Fee Related
- 2005-08-29 CN CN2005800369528A patent/CN101048140B/zh not_active Expired - Fee Related
- 2005-08-29 WO PCT/US2005/030542 patent/WO2006026501A1/en active Application Filing
- 2005-08-29 DE DE602005007048T patent/DE602005007048D1/de not_active Expired - Fee Related
-
2011
- 2011-11-23 US US13/303,565 patent/US20120142741A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2006026501A1 (en) | 2006-03-09 |
CN101048140B (zh) | 2013-06-19 |
CN101048140A (zh) | 2007-10-03 |
EP1796642B1 (de) | 2008-05-21 |
US20120142741A1 (en) | 2012-06-07 |
CA2578442A1 (en) | 2006-03-09 |
JP2008511686A (ja) | 2008-04-17 |
US20060078617A1 (en) | 2006-04-13 |
MX2007002398A (es) | 2007-05-15 |
ES2306216T3 (es) | 2008-11-01 |
EP1796642A1 (de) | 2007-06-20 |
JP5128948B2 (ja) | 2013-01-23 |
DE602005007048D1 (de) | 2008-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE395905T1 (de) | Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs | |
TW200616627A (en) | New pharmaceutical compositions for the treatment of hyper-proliferative disorders | |
MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
ATE492542T1 (de) | Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas | |
TW200700093A (en) | Pharmaceutical composition for the treatment of cancer | |
MX2010014233A (es) | Compuestos quimicos 251. | |
ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
DE602006014579D1 (de) | Heteroalkylgebundene pyrimidinderivate | |
TW200608979A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
MY143795A (en) | Tetrahydropyridoindole derivatives | |
GB0305152D0 (en) | Organic compounds | |
EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
TW200738659A (en) | Novel compounds | |
TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
WO2007067519A3 (en) | The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions | |
BRPI0508177A (pt) | composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação | |
TW200731975A (en) | Novel combinations of medicaments for the treatment of respiratory diseases | |
WO2007076087A3 (en) | 3-aryl-substituted quinazolones, and uses thereof | |
TW200628473A (en) | Novel heterocycles | |
MX367131B (es) | Sales de xantilio 3,6-disustituidas. | |
MY146802A (en) | Novel drugs for treating respiratory diseases | |
WO2007130501A3 (en) | Combination therapy for treatment of cancer | |
ATE475408T1 (de) | Formulierungen von tipifarnib zur intravenösen verabreichung | |
WO2009151495A3 (en) | Oxazole compounds, compositions and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |